Want to see SE:SCIB full AI Analyst Report?
SCIB Stock Chart & Stats
kr0.33
>-kr0.01(-1.65%)
At close: 4:00 PM EST
kr0.33
>-kr0.01(-1.65%)
Day’s Range― - ―
52-Week Rangekr16.67 - kr54.00
Previous CloseN/A
Volume1.41K
Average Volume (3M)318.73K
Market Cap
kr304.71M
Enterprise Valuekr239.58
Total Cash (Recent Filing)kr71.25M
Total Debt (Recent Filing)kr23.93M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.94
Shares Outstanding10,225,300
10 Day Avg. Volume218,776
30 Day Avg. Volume318,725
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.33
Revenue Forecast (FY)kr65.90M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent top-line expansion (about +13% TTM and multi-year growth) indicates increasing clinical adoption of the Nevisense platform and expanding market penetration. Durable revenue growth supports future scale benefits, helps absorb fixed costs and underpins long-term commercial traction.
Healthy Gross MarginA ~59% TTM gross margin reflects resilient unit economics for the diagnostic platform, implying core product sales generate meaningful contribution per test. This margin profile is a durable foundation for reinvesting in commercial expansion and product support while improving leverage as volumes grow.
Recurring / Hybrid Business ModelThe business combines one-time device sales with recurring consumable/service income, creating lifecycle revenue and customer stickiness. This hybrid model yields repeatable revenue streams that can become more predictable as installed base and test volumes increase, supporting long-term cash generation.
Bears Say
Large Cash BurnVery negative operating and free cash flow (~-85M TTM) shows the company is a material cash burner. Persistent outflows force reliance on external financing, constrain strategic flexibility, and raise the probability of dilutive capital raises if profitable scale or positive cash conversion isn't achieved within the next several quarters.
Severe Operating & Net LossesExtremely negative operating and net margins indicate the cost base far exceeds current revenue levels. Such deep losses reflect that scale and/or structural cost reductions are required before profitability; until then, returns on invested capital and shareholder value remain under pressure.
Funding / Dilution Risk From Volatile EquityHistorically volatile and at times very low equity increases the likelihood management will need to issue capital to fund operations. Even with moderate debt, weak returns and low equity amplify dilution risk, complicating long-term planning and potentially limiting ability to pursue large commercial investments without shareholder dilution.
SciBase Holding AB News
SCIB FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was kr16.67 and its highest was kr54.00 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is kr304.71M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is Aug 19, 2026 which is in 14 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on May 07, 2026. The company reported -kr3 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 10,225,300 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -kr3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.618%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in SE:SCIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Arcoma AB
―
Neola Medical AB
―
Iconovo AB
―